Eusebio Manchado

Also affiliated with Novartis Institutes for BioMedical Research

MedicinePharmacology, Toxicology and PharmaceuticsBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung Adenocarcinoma”.

Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung Adenocarcinoma

Cancer Discovery(2023)10.1158/2159-8290.cd-23-0289

N/A

0.641DataRank · unranked

71 citations

Xueqian Zhuang, Chun‐Hao Pan, Yan Yan, Rohit Thummalapalli, Jill Hallin +12 more

Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations

JTO Clinical and Research Reports(2021)10.1016/j.jtocrr.2021.100256

N/A

0.396DataRank · unranked

13 citations

Eusebio Manchado, Matthew J. Bott, Linda S. Ahn, Yosef Y. Tobi, Andy Ai Ni +14 more

Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinoma

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.09.29.560194

N/A

0.165DataRank · unranked

2 citations

Xueqian Zhuang, Chun‐Hao Pan, Yan Yan, Rohit Thummalapalli, Jill Hallin +12 more